Search Femetric

Search peptides, goals, protocols and references

Weight ManagementAppetiteGlucose / InsulinFat Loss

RESEARCH REFERENCE

Liraglutide

An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.

02

How this works

Liraglutide activates the GLP-1 receptor. Its daily pharmacologic and trial structure differs from longer-acting weekly GLP-1 receptor agonists.

03

Benefits + side effects

Potential Benefits

  • Weight Management
  • Appetite
  • Glucose / Insulin
  • Fat Loss
10

References

01
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine · 2015 · DOI 10.1056/NEJMoa1411892
CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.
By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.
NEXT RESEARCH ACTION
Was this useful?